1 The aim of the study was to investigate the interactions between angiotensin II (All) and adrenoceptor-mediated pressor responses in the pithed rat. Emphasis was placed on the effects of All on blood pressure per se and the possibility of differential effects on a,-and a2-adrenoceptor-mediated pressor responses. 2 A low concentration of the angiotensin converting enzyme (ACE) inhibitor, teprotide
Introduction
The pithed rat has been used to assess the mechaadrenoceptor-mediated pressor responses has been nisms by which angiotensin II (All) might maintain studied by blocking All production with angiotensin vascular tone (Hatton & Clough, 1982; Antonaccio, converting enzyme (ACE) inhibitors or by competi-1985) . The effectiveness of All as a modulator of tive All-receptor blockade with, for example, saralasin, but interpretations of the mechanisms involved Time (min) Figure 1 The effects of teprotide (1 mgkg 1) and the subsequent infusion of angiotensin II (All, on the pressor responses to bolus injections of (a) angiotensin I (Al) (0.5 jugkg-1), (b) may be due to the fall in blood pressure per se evoked by these agents (de Jonge et al., 1982) . It is therefore important to clarify whether the fall in blood pressure is the only factor or whether some more specific action is needed to explain why antagonism of the renin-angiotensin system attenuates adrenoceptor-mediated pressor responses. Some controversy has surrounded the question of whether infusion of All could 'antagonize' the effect of ACE inhibition. In an earlier study of the sympathetic nerve-mediated pressor responses, we were unable to demonstrate convincingly that endogenous All modulated the response except indirectly and non-specifically through its effect on basal blood pressure (Grant & McGrath, 1988) . This also showed that intravenous infusions of All could reverse the effects of ACE inhibitors but only provided that a cyclo-oxygenase inhibitor was administered. The present study attempts to clarify whether pressor responses to agonists behave in the same way.
Noradrenaline increases blood pressure in the pithed rat by interacting with two types of postjunctional a-adrenoceptors (al and a2) (Starke, 1981; McGrath, 1982) . Following experiments employing converting enzyme inhibitors, the AII-receptor antagonist, saralasin, and a limited number of aadrenoceptor agonists, it was suggested that pressor responses to a2-adrenoceptor-mediated stimulation in the pithed rat are modulated by All, whilst a1-adrenoceptor-mediated responses are relatively unaffected (de Jonge et al., 1982; Timmermans et al., 1982) . Another aim of this study was, therefore, to investigate whether the modulatory effects of All were dependent on adrenoceptor subtype. The results suggest that there is a real interaction between endogenous All and pressor responses to a-adrenoceptor agonists which is specific for them compared with other pressor stimuli but there is no differentiation between al-and x2-subtypes.
Preliminary communications of these results have been published (Grant & McGrath, 1984a; .
Methods
Male Wistar rats (245-265 g) were pithed under halothane anaesthesia by the method of Gillespie et al. (1970) . Carotid arterial pressure was recorded and the heart rate was derived from this by an instantaneous rate-meter. Rats were ventilated at 2.5 ml per stroke (60 strokes min-) with a 40% 02:60%N2 gas mixture to produce physiological arterial blood gas tensions (Grant et al., 1984; Grant & McGrath, 1984b) .
Rapid intravenous injections (i.v.) of drugs were made via the left jugular vein in a fixed volume of 1 ml kg'-I (i.e. 0.25 ml for a 250 g rat) washed in by a similar volume of saline. Infusions of drugs were given via the right jugular vein at a rate of 1.5mlh-1. Teprotide (1 mgkg-) produced a mean fall in diastolic blood pressure (BP) of 14 + 0.4 mmHg (n = 24) (combined data from experiments with noradrenaline, phenylephrine, xylazine and Al). As shown in Figure la , teprotide (1 mg kg-1) attenuated the pressor response to Al (0.5 pg kg-') by 77% (P < 0.001, n = 6). Since pressor responses to Al depend on its conversion to All by ACE, this indicates a marked inhibition of ACE. Infusion of All (50ngkg-'minm') in the presence of teprotide restored the basal diastolic BP to levels that were not significantly different from controls (see Table 1 ).
Doses of agonists were chosen to give peak pressor responses which were submaximal and within the range 40-60mmHg, except for tyramine which gave slightly smaller responses.
Noradrenaline The control pressor response to noradrenaline (1 ygkg-') was biphasic: a fast initial increase in diastolic BP was followed by a more prolonged secondary phase response. The whole pressor response lasted approximately 4-5 min. Teprotide (1 mg kg 1) had little effect on the early peak response measured at 20s but significantly attenuated the late phase of the response to noradrenaline measured at 80s (P < 0.001, n = 6). Infusion of All (50 ng kg' min' -) failed to reverse the effects of teprotide on the late phase of the response but significantly potentiated the early peak (P < 0.05, n = 6) (Figure lb).
Phenylephrine The control pressor response to phenylephrine (3 pgkg -) was biphasic: a fast initial increase in diastolic BP was followed by a more prolonged secondary response. The whole response lasted approximately 4 min. Teprotide (1 mg kg 1) had no effect on the early peak but significantly attenuated the late phase of the response to phenylephrine measured at 80s (0.001 < P < 0.01, n = 6).
Infusion of All (50ngkg-'minm ) failed to reverse the inhibitory effect of teprotide on the late phase of the response but produced a small, significant potentiation of the early peak measured at 10s (0.001 < P < 0.01, n = 6) ( Figure 2a ). Xylazine The control response to xylazine (0.5mg kg-') consisted of a fairly rapid initial increase in diastolic BP (slower than for noradrenaline or phenylephrine) followed by a rather prolonged second phase. The entire whole response lasted approximately 12-15 min. Teprotide Figure 2 The effects of teprotide (1 mgkg 1) and the subsequent infusion of angiotensin II (All, 50ngkg-min-1) on the pressor responses to bolus injection of (a) phenylephrine (3.pgkg-1), (b) (1 mg kg-1) had no effect on the initial peak response but markedly attenuated the late phase of the response measured at 4min (P < 0.001, n = 8). Infusion of AII (50ngkg-min-1) partly reversed the inhibitory effect of teprotide on the late phase of the response but this may have been due to the large (35%) potentiation of the early peak response measured at 30 s (P < 0.001, n = 8) ( Figure 2b ).
Other sympathomimetic agents A similar pattern emerged when the effects of teprotide were studied on pressor responses to azepexole (BHT 933) (0.25mgkg-1) ( Figure 2c ) and the indirect sympathomimetic, tyramine (0.2mg kg-1) ( Figure ic) . The late phases of the responses to these agonists were attenuated by teprotide (lmgkg-1) but the peak responses were unaffected. Infusion of All (50ngkg-min-1) only partly antagonized the effects of converting enzyme inhibition on responses to azepexole and tyramine, potentiating the peak to beyond control levels but not fully restoring the late phase, i.e. qualitatively like xylazine.
Effects ofa high dose ofteprotide on pressor responses to a-adrenoceptor agonists given rapidly i.v.
Teprotide (10mgkg-1) produced a fall in diastolic BP of 13 + 0.7 mmHg (n = 20) (combined data from experiments with AI, noradrenaline, phenylephrine and xylazine), which was not significantly different from the effect of teptrotide (1 mg kg 1). However, infusion of All (5Ongkg 1 min-1) did not overcome this depressor effect (Table 2) . Teprotide (10mgkg-1) significantly attenuated the peak responses to noradrenaline (1 pg kg-1; by 50%, P < 0.001, n =6), xylazine (0.5mgkg-'; by 57%, P < 0.001, n =4) and phenylephrine (3ygkg-1; by 60%, P < 0.001, n = 5) (Figure 3b ,d,e), azepexole (0.25 mgkg-1; by 29%, P < 0.05, n = 4) and indanidine (0.Smgkg-', by 39%, P < 0.05, n = 5-7: in this case only, the data are unpaired, reproducible responses were unattainable due to tachyphylaxis to indanidine; n = 7 for control rats, n = 5 for teprotide-treated rats) (Figure 4 ).
Infusion of All (SOng kg-1 min -1) failed to antagonize this inhibitory effect on peak responses to noradrenaline and phenylephrine; however, it did antagonize the effects of teprotide on the peak response to xylazine, azepexole and indanidine (Figure 3b, de; 4ab) .
Effects ofa high dose ofteprotide on pressor responses to a-adrenoceptor agonists: pretreatment with flurbiprofen
Rats were pretreated with the cyclo-oxygenase inhibitor flurbiprofen (5 mg kg-1) 15 min before other drugs were administered. This had no significant Phe +flur 39 ± 1.5 25 ± 2.9 (***) 50 ± 2.6 (*) Xyl 41 ± 3.7 26 ± 3.8 (***) 31 ± 4.1 (*)
Note that AII infusion fails to restore diastolic BP unless rats are pretreated with fluribiprofen 5 mgkg1l (+ flur).
Comparison of the effects of treatments compared with controls (C) were made with a paired t test. (NS = not significant, P > 0.05; * 0.01 < P < 0.05; **0.001 < P < 0.01; ***P < 0.001. Means ± s.e. shown.
effect on the resting diastolic BP. Teprotide (10mg kg-') produced a fall in diastolic BP of 14 + 1.3 mmHg (n = 9) (combined data from experiments with noradrenaline and phenylephrine) and significantly attenuated the peak pressor responses to noradrenaline (1 pgkg-1; by 47%, P < 0.001, a 80 b n = 5), phenylephrine (3ugkg-1; by 58%, P < 0.001, n = 4) (Figure 3c and f) and xylazine (0.5mg kg-; by 57%, P < 0.001, n = 4). Infusion of All (50 ng kg-min 1) in the presence of teprotide increased the basal diastolic BP to values significantly greater than the control levels n=4 n=4 n=4 Figure 3 The effects of teprotide (lOmgkg-1) and the subsequent infusion of angiotensin II (All, 50ngkg-1) on the peak diastolic blood pressure responses to (a) angiotensin I (Al) (0.5pgkg-1), (b) noradrenaline (1pgkg-1), (c) (see Table 2 ). Furthermore, the inhibitory effects of teprotide against noradrenaline and phenylephrine were antagonized by the infusion of AI: pressor responses were not significantly different from controls without teprotide (Figure 3c and f). These two 0 1 2 3 4 5 6 7 8 9 10 11 12
Time (min) Figure 5 After pretreatment with flurbiprofen (5mgkg- actions contrast with the experiments in the absence of a cyclo-oxygenase inhibitor, in which the preteprotide situation was not restored by All infusion (Figure 3b and e: Table 2 ). zine (0.5mgkg-1) in flurbiprofen-pretreated rats are shown in Figure 5 . Responses were essentially restored to control values.
Effects of teprotide on pressor responses to 5-hydroxytryptamine and angiotensin II
The effect on arterial blood pressure of a bolus of 5-HT (O.1 mgkg-') was biphasic, consisting of a rapid initial increase in diastolic BP followed by a small, transient decrease in diastolic BP to below initial baseline. Teprotide (lOmgkg-1) decreased diastolic BP by 18 + 1.9 mmHg but had no significant effect on the height of the pressor response to 5-HT ( Figure 6 ). The small depressor response to 5-HT was significantly attenuated by teprotide (P < 0.001, n = 4) but the absolute value of the nadir of this response was similar to control. 5-HT (O.1 mg kg -) also increased heart rate by approximately 30 min -. This was not significantly altered by pretreatment with teprotide lOmgkg-1 ( Figure  6b ). Both phases of this blood pressure response to 5-HT have been shown to be resistant to prazosin (1 mg kg-1) but the pressor response is susceptible to mianserin (1 mg kg-1) (Barnett et al., 1980) . Similarly, pressor responses to the rapid i.v. injection of AII (400 ng kg-1) were not significantly affected by teprotide (1 and lOmgkg-1) (Figure 7) .
Effects ofsaralasin on pressor responses to oz-adrenoceptor agonists
Continuous infusion of saralasin (4ygkg 1min 1) produced a mean fall in diastolic BP of 11 + 0.6 mmHg (n = 24) (combined data from experiments with All, noradrenaline, phenylephrine and xylazine). As shown in Figure 8a , saralasin 4pgkg-1min-1 significantly inhibited the pressor response to All (400ngkg-1) by 72% (P <0.001, n = 9), indicating that this dose of saralasin effectively blocks those All receptors on vascular smooth muscle that initiate pressor responses in the pithed rat.
As shown in Figure 8b , c and d, saralasin (4ygkg-1min-1) significantly inhibited the peak pressor responses to noradrenaline (lpgkg-'; by 35%, 0.001 < P < 0.01), phenylephrine (3pgkg-1; by 33%, 0.001 < P < 0.01, n = 4) and xylazine (0.5mgkg-1; by 52%, P <0.001, n = 6), indicating that it blocks the All receptors which are responsible for the modulation, by endogenous All, of aadrenoceptor-mediated pressor responses. After teprotide (10mg kg 1), saralasin (4upg kg1 min 1) had no further effect on responses to pressor agonists (results not shown).
Effects ofteprotide on pressor responses to noradrenaline infusion
Noradrenaline infusion (1 ygkg 1min ')produced a pressor response reaching a maximum of approx 60mmHg, comparable to a lgkg-' bolus. This response was inhibited to a significantly greater degree by teprotide (lOmgkg-1) than was the peak response to a rapid injection of noradrenaline ( Figure 9 ).
Discussion
The evidence overall indicates that removal of endogenous All in the pithed rat attenuates aadrenoceptor-mediated responses irrespective of the adrenoceptor subtype activated. We are confident that the doses of the adrenoceptor agonists chosen for this study were selective for a,-and a2-adrenoceptors. For example, in the pithed rat the pressor response to the al-adrenoceptor agonist, phenylephrine, was almost abolished by prazosin (1 mg kg-1) but was not significantly affected by Wyeth 26703 (1 mgkg -) . In contrast, we have previously found (Grant & McGrath, unpublished observations) The lower concentration of the ACE-inhibitor teprotide (1 mgkg-1) employed in this study had no effect on the peak responses to a-adrenoceptor agonists in the pithed rat but significantly attenuated the late, second component of pressor responses. This effect occurred irrespective of adrenoceptor subtype activated but it was more pronounced with the a2-adrenoceptor agonists since these induced a more distinct second component. Since the pressor response to AI was markedly attenuated, this low dose of teprotide (1 mgkg') presumably produced a clear inhibition of ACE.
The higher dose of teprotide (lOmgkg 1) lowered diastolic BP to the same extent as the low dose and had only a small further effect on depression of the response to Al. However, this high dose not only inhibited the second phase components of the responses to a-adrenoceptor agonists but also significantly inhibited the peak responses. This effect occurred irrespective of adrenoceptor subtype since responses to the relatively selective a1-adrenoceptor agonists phenylephrine and indanidine and to the relatively selective a2-adrenoceptor agonists azepexole and xylazine were attenuated.
Also, we have demonstrated that pressor responses to noradrenaline, phenylephrine and xylazine were attenuated by the All-receptor antagonist, saralasin, an effect similar to that of the high dose of teprotide.
It has been shown that responses to the preferential a2-adrenoceptor agonist, clonidine, and the relatively selective a1-adrenoceptor agonist, phenylephrine, are attenuated by captopril (Clough et al., 1983) . Also, Richer et al. (1984) showed that captopril and enalopril reduced, to the same extent, pressor and regional vasoconstrictor responses to the aadrenoceptor agonists, cirazoline (a) and UK14304 (@2) in pithed spontaneously hypertensive rats. In these latter studies, the rats were pretreated daily with ACE inhibitors for 7 days before pithing. All of these results suggest that ACE-inhibition does not selectively antagonize a2-receptor-mediated responses and hence oppose the view of de Jonge et al. (1982) , whose conclusions were based on studies using a limited number of a-adrenoceptor agonists.
At first it appeared that the inhibition of aadrenoceptor-mediated responses by teprotide was not necessarily due to the removal of the influence of endogenous All. We found that infusion of All failed to reverse all of the effects of teprotide, viz. (1) After the low dose of teprotide, All failed to restore the late phase of the responses to a-adrenoceptor agonists, yet it did produce potentiation of the early peak responses. (2) Infusion of All failed to restore the effects of a high dose of teprotide on responses to a-adrenoceptor-agonists except in the cases of xylazine and azepexole. (3) Restoration, by All infusion, of the fall in blood pressure which teprotide produced was not straightforward: with the lower dose of teprotide, the mean diastolic BP was returned to the control value but the effect in individual rats was very variable and with the higher dose of teprotide very little restoration could be produced.
However, this picture was radically altered by pretreating with the cyclo-oxygenase inhibitor, flurbiprofen. Responses to noradrenaline and phenylephrine (i.e. peak and late phase responses) could be restored by infusion of All and, even after the high dose of teprotide, the blood pressure was restored to control levels. Thus it appears that the effects of teprotide can be accounted for by ACE inhibition but All infusion is complicated by its effects on prostaglandin release. The ability of exogenous All to antagonize the effects of ACE inhibition may be hidden by the effects of prostaglandins released by exogenous All, which act in physiological opposition to the vascular effects of All and of a-adrenoceptor agonists. In an earlier study, where we found a similar interaction of cyclo-oxygenase products with nerve-mediated pressor responses, we could not tell whether the effect of cyclo-oxygenase products was pre-or postjunctional (Grant & McGrath, 1988) . The present evidence suggests that this is postjunctional.
In retrospect, the infusion dose of All which we employed (50ngkg-1 min-1) seems to be more than is necessary to restore All levels after teprotide. This became evident only after we used flurbiprofen and may account for the excessive potentiation of the initial peak responses. In our earlier study (Grant & McGrath, 1988) , after teprotide (1 mg kg-'), we failed to restore the initial blood pressure even when infusing the higher dose of All of 200pug kg-1 min-'.
It seems also that pressor responses to xylazine, azepexole and indanidine are relatively less markedly inhibited by prostaglandins, since All infusion, without flurbiprofen, restored their pressor responses after their depression by teprotide. This implies that the facilitatory action of All on the pressor responses to noradrenaline and phenylephrine is selectively 'antagonized' by prostaglandins.
We have no explanation for this other than to suggest that the natural phenylethanolamines act at other sites (or through alternative coupling processes) in addition to those activated by the other agonists and that the interaction of the various modulatory factors is different at these sites, e.g. vasodilator prostaglandins are more effective at the 'phenylethanolamine sites'. There is evidence that noradrenaline and phenylephrine possess peculiar properties distinct from those of other pressor aadrenoceptor agonists since their pressor response on infusion is not maintained (Gillespie & Muir, 1967; O'Brien & McGrath, 1987) . It is possible that they rely more heavily on release of intracellular Ca2 . Whatever the explanation, this cautions against relying on non-phenylethanolamine agonists as tools for unravelling the physiological interactions between catecholamines, angiotensins and prostaglandins.
Of all the pressor stimuli tested in this study, the most susceptible to teprotide was that of infusion of noradrenaline and even the residual response in that case probably has little vasoconstrictor component, since a large increase in heart rate occurs, which is likely to increase cardiac output. In the absence of endogenous All, therefore, it is possible that the infusion of NA may produce no vasoconstrictor response at all. This means that there is a considerable differential effect of All between circulating catecholamines and vasopressor nerves, the former being much more clearly affected (Grant & McGrath, 1988) .
Other evidence confirms that the effects of teprotide are All-dependent. The infusion of the Allreceptor antagonist, saralasin, significantly inhibited the late phase and peak pressor responses to aadrenoceptor agonists. The rate of infusion of saralasin employed in this study significantly attenuated pressor responses to All. Similarly, Hatton & Clough (1982) and Clough et al. (1983) have shown that saralasin significantly attenuated pressor responses to noradrenaline, clonidine and phenylephrine. Also, we have shown that the effects of saralasin and teprotide (10mg kg-1) are not additive against responses to a-adrenoceptor agonists (Grant & McGrath, unpublished observations) .
In our equivalent study of pressor nerve-mediated responses (Grant & McGrath, 1988) , we pursued the argument that pressor nerve responses decline in proportion of the effect of teprotide or saralasin on diastolic BP and that there is, therefore, no need to suggest a physiological interaction between All and the neurotransmission process at the level of vascular smooth muscle. When this is applied to the studies with pressor agonists, the picture is less straightforward. First, a change in blood pressure did not necessarily affect the initial rapid response on injection of agonists. With the low dose of teprotide (1 mg kg-), which did reduce nerve-induced responses, the first phase of the response to agonists was resistant to blockade; in contrast the second, more prolonged component declined to the extent that would have been expected from the fall in diastolic BP, as we found for the nerve-mediated responses. With the higher dose of teprotide, the responses to All and 5-HT remained resistant but now, even the initial rapid responses to aadrenoceptor agonists were attenuated. Thus a real, direct, specific interaction of endogenous All with aadrenoceptor agonists was uncovered with the higher dose of teprotide.
We conclude from this that in the pithed rat model, which was a high endogenous plasma All level (Grant & McGrath, 1988) , interference with the action of endogenous All has a 2-stage effect on adrenoceptor mediated responses. The first stage involves removal of the effect of All on basal blood pressure without necessarily any direct effect on adrenoceptor mechanisms. This action does not attenuate the early rapid responses to agonist bolus injection. In a second stage, exemplified by the high dose of teprotide, a facilitatory influence of endogenous All on both phases of adrenoceptor-mediated vasopressor responses is uncovered: even this action has no influence on the response to bolus injections of 5-HT or All. Neither of these effects shows preference for either of the a-adrenoceptor subtypes.
We concluded in our previous paper (Grant & McGrath, 1988 ) that pressor nerve-mediated vasoconstriction is not affected by endogenous All but in the present study, we conclude that vasoconstrictor responses to exogenously administered aadrenoceptor agonists are facilitated by endogenous All. This differential facilitation of agonist responses correlates also with the effects of prolonged infusion of subpressor doses of All in the pithed rat model: nerve-mediated pressor responses were not affected (Grant & McGrath, 1988) , whereas responses to aadrenoceptor agonists were potentiated (this study). There are insufficient data for further analysis of this phenomenon in the present study but the evidence points quite clearly, in this model, to facilitation of the effects of agonists acting on vascular smooth muscle which does not extend to the actions of the neurotransmitters involved in sympathetic nervemediated vasoconstriction, although a portion of this response is mediated by a-adrenoceptors (Flavhan et al., 1985) . We are currently assessing whether our failure to find a modulatory effect of All on sympathetic vasoconstriction (Bulloch & McGrath, 1986; might arise because the nervemediated response involves both purinergic and aadrenergic components.
